# Comparison of Evolut FX Versus Sapien 3 Ultra Resilia.

Study · id `cardio:ct-nct06470022` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06470022](<https://clinicaltrials.gov/study/NCT06470022>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06470022

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 1370 participants.

## Technical summary

Registry record NCT06470022. Randomized; no masking; primary purpose treatment. Start 2024-08-09 (actual); primary completion 2027-07-14 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 1370 participants (enrolled count; ClinicalTrials.gov record NCT06470022, source copy `cardio:ctgov-nct06470022-2026-08-25`, retrieved 2026-10-26)
- Started: 2024-08-09 (actual) (ClinicalTrials.gov record NCT06470022, source copy `cardio:ctgov-nct06470022-2026-08-25`, retrieved 2026-10-26)
- Primary completion: 2027-07-14 (anticipated) (ClinicalTrials.gov record NCT06470022, source copy `cardio:ctgov-nct06470022-2026-08-25`, retrieved 2026-10-26)
- Completion: 2036-11-20 (anticipated) (ClinicalTrials.gov record NCT06470022, source copy `cardio:ctgov-nct06470022-2026-08-25`, retrieved 2026-10-26)
- Countries: Denmark (ClinicalTrials.gov record NCT06470022, source copy `cardio:ctgov-nct06470022-2026-08-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06470022-2026-08-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparison of Evolut FX Versus Sapien 3 Ultra Resilia.
- Acronym: COMPARE-TAVI
- Condition: Aortic Stenosis
- Intervention (Device): Medtronic Evolut FX
- Intervention (Device): Edwards Sapien 3 Ultra Resilia
- Lead sponsor: Christian Juhl Terkelsen
- Lead sponsor class: OTHER
- Collaborator: Department of Clinical Epidemiology, Aarhus University, DK-8200 Aarhus N, Denmark
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)

## Provenance

Content hash: 32f9223d74990672be795bd3050e5cd84f2be49180f850050be35edded28474c
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
